RECENT PLACEMENT

Occam Places Phil Tagari as CSO at insitro

Occam Places Phil Tagari as CSO at insitro

insitro, a Casdin/ARCH/GV investment, is a data-driven drug discovery and development company using machine learning and computation at scale to transform the way that drugs are discovered and developed for patients. Since its founding in mid-2018, the San Francisco-based company has raised over $800M from top tech, biotech, and crossover investors.

Philip Tagari was placed as insitro’s CSO in late 2022. Tagari joined insitro following a 24-year career at Amgen, where he led the organization's research platforms for over a decade as Vice President, Research - Therapeutic Discovery.

‍

Recent Placements

  1. Avirup Bose, Ph.D., as Chief Business Officer of Iktos
  2. Steve Harrison as CSO at Nucleome
  3. Aimee Einstein as VP of People & Culture at SI-BONE
  4. David Brower as CBO for Oncology Biotech Accent Therapeutics
  5. Annette Matthies as CBO at Elicio Therapeutics
  6. Steve Staben as CSO at Lycia Therapeutics
About Occam Global

Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.